Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial

Journal:
The Lancet
Published:
DOI:
10.1016/s0140-6736(25)01176-6
Affiliations:
7
Authors:
10
Go to article
Institutions Authors Share
Novo Nordisk, Denmark
9.000000
 0.90
ICON - USA, United States of America (USA)
1.000000
 0.10
Interested in Pharmacology and Pharmaceutical Sciences?